Isoform?resolved target discovery and validation in cancer
Active Grant Awarded Last action
- Award ID
- R43CA314782
- Recipient
-
Neosplice Therapeutics, Inc. UEI ZJHHBAXNB7B8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $406,500
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date 21% complete
- Place of performance
- New York, NY 10012, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Cancer Institute, awarded Neosplice Therapeutics, Inc. $406,500 under Grant R43CA314782 on September 9, 2026, through the Cancer Treatment Research program (CFDA 93.395). The award funds a Phase I Small Business Innovation Research project to establish and validate a pipeline for discovering and validating tumor-specific protein isoforms as cancer therapy targets.
Aim 1 applies long-read single-cell and bulk RNA sequencing to define isoform repertoires in endometrial cancer and non-small cell lung cancer. Aim 2 trains a deep learning model, NeoSpliceAI, to impute full-length isoform usage from short-read data across large patient cohorts. Aim 3 deploys NeoSplice-Seq, a proprietary high-throughput assay compatible with FFPE tissues, to validate candidate isoforms at single-cell resolution, including isoforms from immune and stromal populations in the tumor microenvironment as well as malignant cells.
The obligated amount is $406,500. The period of performance runs from the September 9, 2026 award date to an ultimate completion date of August 31, 2027. Place of performance is New York, NY 10012, USA.
Description
- Abstract
- Neosplice therapeutics is developing an isoform-resolved target discovery platform to address one of the most pressing challenges in oncology: the shortage of novel, tumor-specific targets for antibody and T cell- based therapies. Despite major advances in immunotherapy, most patients fail checkpoint inhibitors, underscoring the urgent need for safer, more selective targets. Current therapies rely on a narrow set of well- studied proteins that are also expressed in healthy tissues, leading to on-target/off-tumor toxicities and dose- limiting side effects. Alternative splicing, which occurs in >95% of human genes, creates a vast and underexploited pool of disease-restricted protein isoforms with the potential to serve as highly selective therapeutic targets. The goal of this phase I sbir is to establish and validate a pipeline for systematic discovery and validation of tumor-specific isoforms. Aim 1 will use long-read single-cell and bulk RNA sequencing to define isoform repertoires in endometrial cancer (EC) and non-small cell lung cancer (NSCLC). Aim 2 will expand these discoveries across large patient cohorts by training a deep learning model (NEOSPLICEAI) to impute full-length isoform usage from short-read data. Aim 3 will deploy neosplice-SEQ, our proprietary high-throughput assay compatible with ffpe tissues, to validate candidate isoforms at single-cell resolution across large patient cohorts. Importantly, our single-cell methodology captures isoforms not only from malignant cells but also from immune and stromal populations in the tumor microenvironment- areas that remain largely unexplored and could yield transformative therapeutic opportunities. Unlike existing approaches, which rely on bulk short-read sequencing or antibody reagents, our platform uniquely integrates long-read discovery, ML expansion, and ffpe-based single-cell validation into the first scalable framework for isoform-resolved target discovery. By the end of phase I, neosplice will nominate a prioritized list of validated isoform targets with tumor-restricted expression, ready for phase II antibody or T-cell engager (TCE) development. This platform directly addresses pharma's growing demand for differentiated targets to fuel ADC and TCE pipelines, offering a scalable, end-to-end route to safer and more selective immunotherapies. 1
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $406,500 |
Quick answers
Who received award R43CA314782?
R43CA314782 was awarded to Neosplice Therapeutics, Inc. by National Cancer Institute (National Institutes of Health) on September 9, 2026.
How much is award R43CA314782 worth?
$406,500 has been obligated on R43CA314782.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award